Safety
| Group analyses | Present treatment analyses | |||||||
| Baricitinib strategy | % of total | TNFi strategy | % of total | Total | Patients on baricitinib | Patients on TNFi | Total | |
| SAE: | 6 | 6.2 | 5 | 4.9 | 11 | 6 | 4 | 10 |
| ‘cancer’ | 0 | 0.0 | 2 | 2.0 | 2 | 0 | 2 | 2 |
| ‘GI complication’ | 0 | 0.0 | 2 | 2.0 | 2 | 0 | 1 | 1 |
| ‘infections’ | 3 | 3.1 | 0 | 0.0 | 3 | 3 | 0 | 3 |
| ‘total knee arthroplasty’ | 1 | 1.0 | 0 | 0.0 | 1 | 1 | 0 | 1 |
| ‘MI’ | 1 | 1.0 | 0 | 0.0 | 1 | 1 | 0 | 1 |
| ‘fracture’ | 0 | 0.0 | 1 | 1.0 | 1 | 0 | 1 | 1 |
| ‘cerebral concussion’ | 1 | 1.0 | 0 | 0.0 | 1 | 1 | 0 | 1 |
| AE | 111 | 144 | 255 | 115 | 129 | 244 | ||
Present treatment analyses: (s)AE event developed while on either baricitinib of TNFi. N baricitinib strategy group: 97, N TNFi strategy group: 102, number of patients receiving baricitinib at any point during study: 124, number of patients receiving TNFi at any point during study: 117.
AE, adverse event; GI, gastrointestinal; MI, myocardial infraction; SAE, serious adverse events; TNFi, tumour necrosis factor inhibitors.